Free press releases distribution network?

Agency / Source: Frost & Sullivan

Check Ads Availability|e-mail Article


Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!



Novel Drug Delivery Mechanisms Offer Significant Potential for the European Pharmaceutical Industry - New analysis from Frost & Sullivan, European Drug Delivery Market-Opportunity Analysis, finds that the European pulmonary drug delivery market earned revenues of $7.00 billion in 2007 and estimates this to reach $12.94 billion in 2014
Novel Drug Delivery Mechanisms Offer Significant Potential for the European Pharmaceutical Industry

 

PRZOOM - /newswire/ - London, United Kingdom, 2008/07/24 - New analysis from Frost & Sullivan, European Drug Delivery Market-Opportunity Analysis, finds that the European pulmonary drug delivery market earned revenues of $7.00 billion in 2007 and estimates this to reach $12.94 billion in 2014.

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

The demand for novel drug delivery systems is rising and pharmaceutical companies have been involved in developing innovative new methods. Impending patent expirations will stimulate a surge in novel drug delivery methods for existing products, while sophisticated reformulation will generate substantial revenues in the European pharmaceutical market.

New analysis from Frost & Sullivan (pharma.frost.com), European Drug Delivery Market-Opportunity Analysis, finds that the European pulmonary drug delivery market earned revenues of $7.00 billion in 2007 and estimates this to reach $12.94 billion in 2014. The analysis also finds that the European transdermal drug delivery market earned revenues of $4.04 billion in 2007 and estimates this to reach $7.87 billion in 2014.

"Drug delivery is a fast growing and highly dynamic segment of the pharmaceutical and biotechnology industry," notes Frost & Sullivan Industry Analyst Sylvia Miriyam Findlay. "Various factors have contributed to the growth of this area, including the poor efficacies of certain drugs, patent expirations and the urgent need for life cycle management facing drugs nearing patent expiry."

However, pharmaceutical companies are looking to enhance the safety record of their products by introducing novel drug delivery technologies. This will also boost their competitive edge and enable them to maximise revenue generation.

The foremost challenge presented by the pulmonary route of drug delivery is the inability to deliver drugs directly to the alveoli. In addition, large molecules do not permeate the skin barrier and hence, fail to be delivered by the transdermal method. Ineffective drug delivery presents a significant technological challenge to market expansion.

"Market participants should focus on developing novel technologies that support the passage of large peptides," notes Findlay. "This will be critical to sustaining market growth, as the pharmaceutical/biotechnology industry is moving towards monoclonal antibody (Mab) therapeutics. Mabs, which are large peptides, are already being used in various therapeutic applications."

If you are interested in a virtual brochure, which provides manufacturers, end users and other industry participants with an overview of the European drug delivery market-opportunity analysis, then send an email to Patrick Cairns, Corporate Communications, at pcairns_pr[.]frost.com, with your full name, company name, title, telephone number, company email address, company website, city, state and country. Upon receipt of the above information, an overview will be sent to you by email.

European Drug Delivery Market-Opportunity Analysis is part of the Pharmaceutical and Clinical Diagnostics Growth Partnership Service Programme, which also includes research in the following markets: European Fibromyalgia Market and European Growth Hormone Market. All research included in subscriptions provide detailed market opportunities and industry trends that have been evaluated following extensive interviews with market participants. Interviews with the press are available.

Frost & Sullivan, the Growth Partnership Company, partners with clients to accelerate their growth. The company's TEAM Research, Growth Consulting and Growth Team Membership™ empower clients to create a growth-focused culture that generates, evaluates and implements effective growth strategies. Frost & Sullivan employs over 45 years of experience in partnering with Global 1000 companies, emerging businesses and the investment community from more than 30 offices on six continents.

European Drug Delivery Market – Opportunity Analysis
M214

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Agency / Source: Frost & Sullivan

 
 

Availability: All Regions (Including Int'l)

 

Traffic Booster: [/] Quick PRZOOM - Press & Newswire Visibility Checker

 

Distribution / Indexing: [+] / [Company listed above is a registered member of our network. Content made possible by PRZOOM / PRTODAY indexing services]

 
 
# # #
 

 
  Your Banner Ad showing on ALL
Pharma/BioTech/Nutrition articles,
CATCH Visitors via Your Competitors Announcements!


Novel Drug Delivery Mechanisms Offer Significant Potential for the European Pharmaceutical Industry

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name PRZOOM - Press & Newswire and LINK as the source.
 
  For more information, please visit:
Is this your article? Activate ALL web links by Upgrading to Press Release PREMIUM Plan Now!
Frost & Sullivan |
Contact: Patrick Cairns 
+27 18 468 2315 patrick.cairns[.]frost.com
 
PRZOOM / PRTODAY - Newswire Today disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any Frost & Sullivan securities in any jurisdiction including any other companies listed or named in this release.

Pharma/BioTech/Nutrition via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY



Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!




Read Latest Press Releases From Frost & Sullivan / Company Profile


Read Pharma/BioTech/Nutrition Most Recent Related Press Releases:

BD Announces Adoption of Windows 10 ‘Internet of Things’ for the Pyxis™ ES System
Greenphire Named to Deloitte 2016 Technology Fast 500™
Genentech Showcases New Clinical Data Across a Variety of Blood Diseases at American Society of Hematology 2016 Annual Meeting
BD Collaborates with JDRF to Focus on Extended Wear Innovations for Insulin Infusion Delivery
BD Launches First Syringe Designed for Use with Humulin® R U-500 Insulin
MDxHealth Announces Unique CPT Code Awarded for ConfirmMDx from the American Medical Association
BD MAX™ Vaginal Panel Receives FDA Market Authorization to Detect Most Common Causes of Vaginal Infections
Greenphire Receives EU-US Privacy Shield Certification
The 2016 Georges Mathé Prize Recognizes Research on the Immunological Determinants of the Response to Breast Cancer Treatment
MDxHealth Announces Agreement with HIFU CLINIC Prostate Cancer Center for Distribution of SelectMDx in Poland

Boost Your Social Network
& Crowdfunding Campaigns


LIFETIME SOCIAL MEDIA WALL
 
NewswireToday Celebrates 10 Years in Business
Find business coaching, life coaching, executive coaching and corporate coaching, best selling coaching books, ...



PREMIUM Members


Visit  La Bella Bakery Artisan Bakery Arizona

Visit  NAKIVO, Inc.

Visit  BizJobs.com







 
  ©2016 PRZOOM — Limelon Advertising, Co.
Home | About PRZOOM | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR free press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneur newswire distribution prtoday.com freenewswiredistribution asianewstoday bizwiretoday USA pr UK today